In an expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, considers what is next for the pharma giant. 17 November 2016
In an expert view piece, Susan Hepworth from the Global Alliance for Patient Access examine the results of biosimilar switching study NOR-SWITCH and what they m 18 October 2016
In our weekly expert view piece, Rohit Malpani, director of policy and analysis for Mèdecins Sans Frontiéres Access Campaign, discusses the UN Secretary General 17 October 2016
In our weekly expert view, head of oncology at German pharma company Bayer looks at the evolution of cancer treatments over the past two decades and looks ahead 5 October 2016
GlaxoSmithKline’s decision to appoint Emma Walmsley as chief executive is a clear commitment to past strategy but an acknowledgement that a fresh, and arguably 20 September 2016
In our weekly expert view piece, Michael Jewell, healthcare partner at Cavendish Corporate Finance, explains why we can expect mid-market companies to press on 20 September 2016
In our weekly expert view piece, pharmacovigilance team leader at Berlin-based CRO, KCR, examines the increasing benefits of post-authorization studies and the 14 September 2016
In our weekly expert view piece, Stacie Ropka, an IP attorney from Axinn Veltrop & Harkrider who focuses her practice on biosimilars, examines the biosimilar ap 6 September 2016
In our weekly expert view piece, Dr Bill Love, chief executive of Destiny Pharma, looks at worrying rises in Methicillin Resistant Staphylococcus aureus (MRSA) 23 August 2016
In our weekly expert view piece, Ed Corbett, engagement manager at specialist management consultancy firm Novasecta, explores the different routes British pharm 18 August 2016
In our weekly expert view piece, Victoria Hordern, privacy and cybersecurity lawyer at Hogan Lovells, examines the UK government's proposals on data security an 9 August 2016
In our weekly expert view piece, patent attorney and head of life sciences at intellectual property firm Withers & Rogers LLP, Adrian Tombling, examines GSK's d 2 August 2016
In our weekly expert view piece, Darren Cooper, director of industry solutions at Stibo Systems examines the implications and potential benefits of the Indentif 19 July 2016
In our weekly expert view piece, John Maloney and Eleanor Tyler, from Bloomberg Law analyze the reasons behind Federal Trade Commission's increased scrutiny on 12 July 2016
In our weekly expert view piece, Dr Alan Marks, chairman of the Alliance for Patient Access examines challenges faced by cancer patients in accessing precision 5 July 2016
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.